Company news

Racura Oncology Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Race Initiates FTO Melanoma Preclinical Study

March 18, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Compelling Preclinical Breast Cancer Results

March 8, 2021

Race receives $387k R&D tax incentive refund

December 16, 2020

Race AGM presentations and strategic update

November 29, 2020

Impressive Preclinical Bisantrene Breast Cancer Results

November 23, 2020

Prof Borje S Andersson appointed Chief Medical Officer

October 1, 2020

Race leadership team strengthened

September 1, 2020

Strategic investors make further $1.5m investment in Race

August 12, 2020

A$3m strategic investment from prominent biotech investors

July 12, 2020

Extension of time to repay loan through share buy-back

June 16, 2020

Impressive 40% response in Phase II Bisantrene AML Trial

June 15, 2020

Managing Director Resignation

May 20, 2020

Race starts preclinical breast cancer study for Bisantrene

May 13, 2020

Race Secures A$1.8m strategic placement

March 5, 2020

December 2019 Quarterly Report

January 29, 2020

Race Receives $159k R&D Tax Incentive Refund

December 16, 2019

Race reveals new strategy for cancer drug Bisantrene

November 14, 2019

Appendix 4C - quarterly

October 17, 2019

Prominent biotech investor leads investment in Race

August 19, 2019

First patient treated in Bisantrene trial in Israel

July 24, 2019

Bisantrene AML trial to start in Israel

May 13, 2019

Bisantrene IND Update

April 24, 2019

Race files Bisantrene IND with FDA

March 24, 2019

Principal Investigator appointed for Bisantrene

February 24, 2019

Race Receives $228k R&D Tax Incentive Refund

January 31, 2019

Race appoints leading haematologist to support Bisantrene

January 21, 2019

Race signs agreement for Bisantrene NPP in Israel

December 16, 2018

Race appoints Biosynergy to pursue Bisantrene licensing

October 31, 2018

September 2018 Quarterly Report

October 25, 2018

Appendix 4E & Financial Statements

August 21, 2018

June 2018 Quarterly Report

July 26, 2018

FDA Grants Bisantrene Rare Paediatric Disease Designation

July 18, 2018

Bisantrene poster presented at French Leukaemia Conference

June 26, 2018

Bisantrene approval in UK for supply as unlicensed medicine

June 21, 2018

RAC cancer drug success in AML reported by French doctors

June 4, 2018

Race executes agreement for Bisantrene clinical trial

May 14, 2018

Race signs global distribution agreement with Durbin PLC

April 10, 2018

Race increases placement to $3.69m

March 16, 2018

Race completes over-subscribed $3.159 million placement

March 11, 2018

Second Bisantrene Patent Allowed in US

February 20, 2018

Notice of Allowance for Bisantrene Patent in US

January 28, 2018

Race Receives $170k R&D Tax Incentive Refund

January 24, 2018

Race Oncology Produces First Batch of Bisantrene

September 11, 2017

Appendix 4E & Annual Financial Statements

August 29, 2017

Issue of Options

August 13, 2017

Peer-Reviewed The Rediscovery of Bisantrene Published

July 19, 2017

Race Completes Over-Subscribed $2.5 Million Placement

July 16, 2017

Race Joint Venture with TargImmune

July 10, 2017

Race Announces NCI Collaboration

July 4, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 33 decks. Every deck is listed under its year.